Immutep’s Analysis of 5,922 Patients Shows Efti Adds 7.7-Month Survival
IMMP•In a pooled analysis of 5,922 late-stage cancer patients across five trials, Immutep’s efti plus standard-of-care induced a statistically significant median overall survival improvement of 7.7 months (p=0.00171) in lymphocyte count responders. Treatment also boosted absolute lymphocyte counts and TH1 biomarkers independent of chemotherapy or PD-1 antagonist partners.
1. Patient Cohort and Trial Scope
The analysis pooled data from 5,922 patients enrolled in five independent clinical studies (TACTI-mel, TACTI-002, TACTI-003, AIPAC, AIPAC-003) spanning four tumor indications: non-small cell lung cancer, head and neck squamous cell carcinoma, metastatic breast cancer and melanoma. All patients received 30 mg subcutaneous efti combined with standard-of-care therapies.
2. Survival Benefit in ALC Responders
Patients classified as absolute lymphocyte count responders in the efti plus standard-of-care group experienced a median overall survival improvement of 7.7 months compared to non-responders (p=0.00171), while no correlation between lymphocyte response and survival was observed in patients receiving standard-of-care alone.
3. Immune Activation and Biomarker Correlations
Treatment with efti plus standard-of-care rapidly elevated circulating absolute lymphocyte counts and TH1-related cytokines, and gene expression profiling revealed enhanced T-cell function scores in responders, demonstrating a clear link between immune activation and clinical efficacy.
4. Program Context and Next Steps
These findings will be presented at the upcoming ASCO 2026 annual meeting, supporting Immutep’s ongoing evaluation of eftilagimod alfa after discontinuing the TACTI-004 Phase III NSCLC trial and guiding future development strategy across multiple cancer indications.
